pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›LETROZOLE
drug
save

LETROZOLE

Marketedupdated 6mo ago
by Yiling Pharmaceutical Ltd
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval32 co-mentions · 16 sources
  • tagSmall Molecule16 co-mentions · 16 sources

indications

investigational
Breast Cancer

all catalysts(9)

approval · 9
Jun 3, 2011
approval
15y ago
LETROZOLE — FDA approval
LETROZOLE
→
May 15, 2012
approval
15y ago
LETROZOLE — FDA approval
LETROZOLE
→
Jul 19, 2014
approval
12y ago
LETROZOLE — FDA approval
LETROZOLE
→
Feb 13, 2015
approval
12y ago
LETROZOLE — FDA approval
LETROZOLE
→
Feb 13, 2015
approval
12y ago
LETROZOLE — FDA approval
LETROZOLE
→
Apr 2, 2021
approval
6y ago
LETROZOLE — FDA approval
LETROZOLE
→
Apr 2, 2021
approval
6y ago
LETROZOLE — FDA approval
LETROZOLE
→
Oct 1, 2025
approval
1y ago
LETROZOLE — FDA approval
LETROZOLE
→
Oct 1, 2025
approval
1y ago
LETROZOLE — FDA approval
LETROZOLE
→
view all 9 catalysts →

Trials studying LETROZOLE

  • phase1A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumorsrecruitingn=66
  • phase2A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancernot yet recruitingn=120
  • phase3Phase IIIb Study of Ribociclib + ET in Early Breast Canceractive not recruitingn=1,466
  • phase2Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumorsrecruitingn=430
  • phase1A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancernot yet recruitingn=165
  • phase3A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancerrecruitingn=450
  • phase3A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrenceactive not recruitingn=4,556
  • phase3Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancerrecruitingn=788

Patent cliff

source: FDA Orange Book
first barrier falls
Sep 17, 2027
304 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (11)

  • Apr 14, 2036formulationUS 10799506
  • Apr 14, 2036formulationUS 12064434
  • Apr 14, 2036formulationUS 12419894
  • Aug 7, 2034method-of-use (U-3998)US 12544380
  • Nov 9, 2031compositionUS 91937325.0y
  • Nov 9, 2031method-of-use (U-3264)US 98687395.0y
  • Mar 13, 2031compositionUS 84153554.3y
  • May 25, 2030compositionUS 86859803.5y
  • Dec 9, 2029method-of-use (U-3264)US 89626303.1y
  • Aug 20, 2029method-of-use (U-3264)US 94161362.8y
  • Jun 17, 2028compositionUS 83242251.6y

FDA exclusivities (1)

  • Sep 17, 2027I-951Indication (3y)304d

News(3)

  • Opinion: Telehealth abortion with mifepristone continues, with backup plans still in place
    Restricting telehealth prescribing of mifepristone wouldn't spell the end of telehealth medication abortion, writes OB-GYN Christine Henneberg.
    stat · 6mo ago
  • Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
    Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.
    onclive · 6mo ago
  • ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
    Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
    onclive · 6mo ago
brand
LETROZOLE
generic
LETROZOLE
indication
Breast Cancer
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?